Drug Type Small molecule drug |
Synonyms (E)-6-(4-chlorostyryl)-1,3,5,-trimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4-(3H,5H)-dione (17f) |
Target |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists), MAO-B inhibitors(Monoamine oxidase B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC17H16ClN3O2 |
InChIKeyCUWBKAWUQFYRQI-RMKNXTFCSA-N |
CAS Registry1419403-68-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Preclinical | IT | 06 Jan 2013 |